Illumina, a pioneering leader in genomics, has successfully raised an impressive $7.1 billion in funding, marking a significant milestone in the company鈥檚 mission to revolutionize personalized medicine through cutting-edge technologies and assays. This substantial investment will fuel Illumina's advancements in the analysis of genetic variation and function, enabling groundbreaking studies that were once considered beyond reach. As the company continues to develop innovative, array-based solutions for DNA, RNA, and protein analysis, these funds will propel ongoing research into disease mechanisms, accelerate drug development processes, and enhance the creation of molecular tests for clinical applications. Illumina's commitment to flexibility and scalability in their offerings ensures that they can adapt to the rapidly evolving landscape of genomic research. Furthermore, with a strong focus on collaborative interactions and customer needs, Illumina aims to continue delivering industry-leading support and service as they drive forward the realization of personalized medicine. By prioritizing innovation and maintaining a robust infrastructure for genetic analysis, Illumina not only seeks to push the boundaries of genomic science but also to empower healthcare providers with the tools necessary for better diagnosis and treatment of diseases. This funding will undoubtedly enable Illumina to remain at the forefront of genomic technology, paving the way for a future where personalized medicine is not merely a vision but a standard in healthcare.
Breaking News: Illumina Secures $7.1 Billion in Funding to Drive Innovations in Genetic Analysis and Personalized Medicine
Recently funded 路 $7.1BBiotechnology Research
Get the full Illumina company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Antares
Energy abundance unlocks progress. It powers missions, grows economies, strengthens national security, and expands what鈥檚 possible on Earth and beyond. But in the places where power is most critical, it鈥檚 often the hardest to deliver. That鈥檚 the problem we鈥檙e solving. At Antares, we鈥檙e building compact nuclear microreactors to deliver reliable, mobile energy where it鈥檚 needed most: remote military bases, austere industrial sites, and, one day, deep space and underwater missions. The U.S. nuclear industry hasn鈥檛 seen true momentum in decades. We鈥檙e moving it forward with urgency, humility, and a commitment to building what鈥檚 needed now. Our team includes engineers and operators from SpaceX, Relativity Space, Ursa Major, the White House, MIT, Rigetti Computing, and the U.S. Air Force. Backed by over $130M from top-tier investors, we鈥檙e focused on shipping hardware not hypotheticals.
$470.0M Series c
today
Pilot Protocol
Virtual addresses, encrypted tunnels, and a trust model that works across any boundary. Open source. IETF drafts submitted. Built by Vulture Labs. Send your agent to pilotprotocol.network
